Cipla secures CDSCO approval for Afrezza, its inhaled insulin, marking a breakthrough in diabetes management with innovative ...

Cipla received approval from India's Central Drugs Standard Control Organisation to distribute and market Afrezza inhalation ...

The CDSCO decision follows existing approvals in the United States and Brazil. “Achieving approval for Afrezza in India, a country with the second highest burden of diabetes worldwide ...

Drugmaker Cipla has got regulatory approval to market Afrezza, a rapid acting insulin delivered through an inhaler, as compared to other insulins given through injections. The Central Drugs ...

The CDSCO decision follows existing approvals in the United States and Brazil. “Achieving approval for Afrezza in India, a country with the second highest burden of diabetes worldwide, is an exciting ...